



## **Prostatype Genomics AB**

Org. 556726-0285

### **Year End Report 2022**

1 January 2022 – 31 December 2022

&

### **Quarterly Report**

1 October 2022 – 31 December 2022

## Quarterly Report

1 October 2022 – 31 December 2022

&

## Year End Report

1 January 2022 – 31 December 2022

### Quarter 4 (1 October – 31 December 2022) summarized

- Net sales amounted to 304 (0) TSEK.
- EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to -7 673 (-5 712) TSEK.
- Cash flow from current operations in the quarter amounted -7 850 (-5 381) TSEK.
- Total cash flow for the period amounted to - 7 950 (-6 216) TSEK.
- Earnings per share amounted to -0,36 (-0,32) SEK.

### Full year (1 January 2022–31 December 2022) summarized

- Net sales amounted to 683 (10) TSEK.
- EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to -26 786 (-15 548) TSEK.
- Cash flow from current operations in the quarter amounted -27 693 (-16 078) TSEK.
- Total cash flow for the period amounted to - 8 840 (4 467) TSEK.
- Earnings per share amounted to -1,27 (-1,04) SEK.



## Vision

Our vision is that doctors and patients, confronted with diagnosed prostate cancer, have full confidence in their treatment decisions.

## Mission

**Prostatype Genomics'** mission is to make a difference in prostate cancer patients' lives through the discovery and commercialization of transformative tests to guide treatment decisions. We can thereby increase quality of life and peace-of-mind for patients and simultaneously reduce health care costs. **Prostatype Genomics** will achieve this by making **Prostatype®** the global test system of choice for newly diagnosed prostate cancer patients.

## Significant events during the Fourth Quarter

### Changes in the sales organization to strengthen sales growth

To strengthen the development, Prostatype Genomics is moving the responsibility for the sales organization to Sweden to ensure that the entire process takes place as uniformly and efficiently as possible. In connection with this, Mats Bergström has been hired as Sales Director EMEA. Mats has a long and solid experience from sales and introduction of new advanced Medtech products and will significantly strengthen the Company's commercial ability. The sales forecast for the year has also been updated to SEK 700,000.

### Emelie Berglund appointed as new Chief Technology Officer

On November 8, Emelie Berglund took over the important role of CTO of Prostatype Genomics from Lidi Xu, who has held the position since 2019. Lidi is leaving the company to move back to China with her family but will continue to work on various projects for Prostatype Genomics. Emelie Berglund has a PhD in Biotechnology from the Royal Institute of Technology in Stockholm, and more than seven years of combined research experience within prostate cancer. After her degree, Emelie has led the R&D operations of a Swedish life science company that develops products in cancer detection and biomarker analysis.

## Significant events during the financial year

### Strengthened commercial organization

Prostatype Genomics continues to strengthen the European sales organization and has hired Albin Bremer as sales manager responsible for the Nordic market. Albin has over 20 years of experience from both sales and sales manager roles in several leading pharmaceutical companies such as Abbott and ALK-Abelló. Most recently, Albin comes from Ipsen where he was involved in starting up and developing the company's oncology division with a strong commercial focus. With many years of experience in prostate cancer, Albin has a great understanding of how the disease affects patients and the challenges healthcare faces when it comes to better prognosticating patients with established prostate cancer.

### Improved availability for laboratories

In collaboration with Karolinska Institutet in Stockholm, Prostatype Genomics has carried out an extensive validation process with the aim of significantly increasing the commercial and technical availability of Prostatype®. By validating laboratory kits from additional suppliers as well as several instruments for RNA amplification, many more laboratories can now perform the test as the results from the validations turned out positive.

### Strong results for Prostatype® in Asian pilot study

The recent study was conducted in China in collaboration with the Nanjing Drum Tower University Hospital, Jiangsu, and Prostatype Genomics' partner GloriousMed based in Shanghai. The study indicates that the clinical performance of Prostatype® in East Asian population is in line with the results previously communicated results in several studies in Caucasian populations.

### The Board proposes to the Annual General Meeting to authorize the Board to decide on a rights issue in order to intensify the launch of the Prostatype® genetic test

In May, the Board of Prostatype Genomics announced that the Company has decided to propose to the next Annual General Meeting to authorize the Board to decide on the implementation of a rights issue of units of initially approximately SEK 22.5 million before issue costs, followed by an additional approximately SEK 22.5 million before issue costs attributable to attached warrants. It is also proposed that the public be given the opportunity to participate. The initial part of the Rights Issue is covered to approximately 100 percent by subscription and guarantee commitments.

The rights issue is proposed to be able to finance and intensify the launch of Prostatype® in the USA and EMEA and to initiate and complete a number of validation studies in selected European markets as well as in the USA and Asia

### Outcome of rights issue of units

The Company's rights issue of units was closed on July 20. The rights issue was subscribed for a total of approximately SEK 17.9 million, including pre-subscription commitments of approximately SEK 8.5 million, corresponding to a subscription ratio of 79.5 percent. In addition, guarantee commitments corresponding to approximately SEK 4.6 million have been activated, meaning that Prostatype Genomics is provided 100 percent of the issue volume. Prostatype Genomics will thus initially receive approximately SEK 22.5 million before deduction of transaction related costs of approximately SEK 3.1 million in total (including compensation to guarantors of approximately SEK 1.4 million). Through the rights issue, 7,755,895 shares and 7,755,895 warrants of series TO 2 are issued. A total of 306,315 units (corresponding to approximately SEK 16.9 million) were subscribed for with the support of unit rights, including subscription commitments of approximately SEK 8.5 million. The allocation of units has been made in accordance with the allocation principles described in the prospectus that was published by the Company on the 28 June 2022.

### **Prostatype Genomics begins collaboration with the Capio Specialist Center in Solna with immediate effect**

In April, the Company announced that it has entered into a cooperation with Capio Solna Urologi and that the first patient has been treated based on the prognostic test result from the use of Prostatype®

### **First order to the UK**

In March, the Company announced that Cambridge Clinical Laboratories (CCL), Prostatype Genomics' partner in the United Kingdom and Ireland, has placed the first order for the Company's genetic test, Prostatype®. This means that Prostatype Genomics has taken another step in the commercialization process in another priority market.

### **The Company establishes subsidiaries in the USA**

In March, Prostatype Genomics announced that the Company is establishing a subsidiary in the United States, Prostatype Genomics, Inc., owned 100% by Prostatype Genomics AB. The establishment of the subsidiary is an important step in the work towards the US market entry.

### **Use period for Prostatype Genomics warrants of series TO 1 begins**

The exercise period for the TO 1 series warrants issued in connection with Prostatype Genomics' issue of units in September 2020 began on 27 January 2022. The exercise period lasted until 17 February 2022.

### **Outcome in option redemption**

On February 17, 2022, the exercise period for Prostatype Genomics warrants of series TO 1 ended, which was issued in connection with the Company's issue of units in September 2020. A total of 14,841 warrants of series TO 1 were exercised.

### **Presentation during the American Urology Association Annual Meeting**

In January, the Company announced that the results of the study conducted by the University Hospital in Uppsala have been selected for presentation during the AUA, American Urology Association Annual Meeting 2022, one of the largest and most important gatherings for urologists in the world, which takes place in New Orleans on 13- May 16 This is an important step in the upcoming launch of Prostatype® in the US market.

## Events after the balance day

### **Prostatype Genomics AB enters agreement with Life Genomics AB**

Prostatype Genomics and Life Genomics start a non-exclusive collaboration meaning Life Genomics will handle all steps in the laboratory process required to analyse Prostatype<sup>®</sup>, Prostatype Genomics' gene test to assess the aggressiveness of prostate cancer. The collaboration means that Prostatype Genomics can further focus on marketing the test to patients and doctors and secures resources to be able to handle the increased demand for Prostatype<sup>®</sup> from patients and healthcare. The agreement applies to all Nordic countries and comes into force immediately.

### **Prostatype Genomics recruits Steven Gaal as President of Prostatype Genomics Inc., USA**

Prostatype Genomics AB has recruited Steven Gaal to the role of President of the company's wholly owned subsidiary, Prostatype Genomics Inc. Steven's task will be to establish and launch Prostatype<sup>®</sup>, the company's genomic test to assess the aggressiveness of prostate cancer in individual patients, in the US market. Steven has over 18 years of experience from leading positions in the sale of cancer diagnostic tools and services and begins his employment with Prostatype Genomics Inc. effective immediately.

## CEO comments

2022 was a turbulent year with Russia's invasion of Ukraine, sharply increasing inflation and in the wake of this, rising interest rates and troubled stock markets. Despite this, 2022 was the year when Prostatype Genomics could seriously reach out to customers and partners after the long-term the pandemic. 2022 was also the year we took the first steps into the American market.

Thus, Prostatype Genomics has taken several important steps forward and it is gratifying to note the concrete successes we see in our priority markets.

The building blocks that make Prostatype Genomics an attractive company and build future value are several:

- 1) To be able to demonstrate continued sales development in the markets where we are present,
- 2) Continuously growing scientific footprint through published studies
- 3) Presence and progress in the United States
- 4) In collaboration with leading partners continue to develop the business

For a relatively small company like Prostatype Genomics, it means several challenges and having the target picture clear to oneself every day, which requires important priorities. Focus and resources must always be allocated in favor of the activities that really build value and external interest for the company.

We have implemented several important and necessary changes in our organization during the second half of the year. In our home market, Albin Bremer took over as responsible for sales within the Nordics after summer. We are already seeing the concrete result of Albin's work in an increased influx of orders of Prostatype® from urologists and patients. Another concrete proof of an increased interest from urologists is that more and more clinics choose to cooperate with us and market this through our patient website, prostatype.se. Currently, there are about 10 clinics that, after validation, have chosen to actively offer Prostatype to patients. This is of course gratifying for us and proof of the added value Prostatype® offers to healthcare as well as patients and relatives.

### Increased focus

During the autumn, we initiated a collaboration regarding the laboratory handling of Prostatype® with the company Life Genomics, a laboratory that provides genetic tests to both private clinics and public healthcare. This business model is about to be launched in other prioritized target markets. The collaboration means that Life Genomics will manage all steps in the laboratory process required to analyze the aggressiveness of cancer using Prostatype®. There is no added value for Prostatype Genomics to manage these processes internally. We can and must instead continue to focus entirely on our two main goals: strengthening our scientific footprint through additional validation studies as well as continuing and accelerating the commercialization of Prostatype® in Europe and the United States.

### Exciting developments in Europe

In addition to a strong tailwind in our Nordic home market, we also see a positive development in several of our priority markets in Europe. The company identified Spain as an important market several years ago, and in line with that, we have strengthened the organization during the autumn with a full-time resource on site. In December, Enrique Manglano started with us, and here too, development has gone faster than we dared to hope for. Several interesting collaborations with leading Spanish clinics and laboratories are expected to start shortly, both in the public and as in private care. It will result in a further strengthened scientific footprint as well as concrete sales – completely in line with our strategy.

At the moment, around 30 hospitals/medical units are evaluating Prostatype®. In addition to these ongoing tests, around 20 units have already evaluated the product with good clinical results and are



preparing to introduce Prostatype® into clinical routine. In the next step, we have a pipeline comprising another 50 or so urological units that are about to initiate their own evaluation of Prostatype®. We can therefore look back on 2022 and state that during the year we succeeded very well in reaching out to our customers.

### Go West...

In parallel with a very exciting development in the Nordics and Europe, the launch in the US continues fully in accordance with the company's offensive plans made possible by the rights issue that was carried out during the year. We have a very ambitious plan for the launch in the US where we have focused on enabling a fast commercial process, while ensuring long-term sustainable development.

The American market is different and far ahead of us in Europe in several areas. Prognostic biomarkers in prostate cancer have been routinely used for more than 10 years and are reimbursed by both Medicare and private insurance companies. In order to gain quick access to the market, a local organization with experience in US urologists, clinics and payment systems is necessary. After an extensive and thorough process, Steven Gaal was recruited as President of Prostatype Genomics Inc., the company's wholly owned US subsidiary. Steven has over 18 years of experience from leading positions in the sales of cancer diagnostic tools and services and has experience and a network of contacts that enable a short starting period.

Also in the US, it is about establishing ourselves scientifically as quickly as possible with the validation studies required to be reimbursed in accordance with the guidelines for prognostic biomarkers applied by Medicare and large private insurance companies. We have good contacts and already initiated collaborations with several leading American urologists, which is of course very important to ensure that we continue to carry out the right activities as cost-effectively and quickly as possible.

To accelerate the commercialization in the USA, the company made the early decision to launch Prostatype® in the USA as an LDT (Laboratory Developed Test) test and to initiate collaboration with a suitable, established laboratory partner, which is one of Steven's main tasks initially. This launch strategy gives the company opportunity to initiate marketing efforts and sales directly to consumers and urologists as soon as possible.

For those of you who have invested in Prostatype Genomics, it is of course encouraging to hear that we continue development in a positive direction and that more and more urologists and patients see the advantages of Prostatype® and also that sales have now started to start after the validations carried out locally. With the interesting development we see in all markets, we are convinced that sales for the year 2023 will increase significantly in relation to 2022. It is also worth remembering that our business model with very high margins means that we quickly reach break-even when sales are taking off in earnest. It is enough for approx. 150 urologists, globally, to start using Prostatype® in clinical routine for us to reach break-even. In other words, it is a highly achievable goal that demonstrates the economic potential that exists in Prostatype Genomics.

We therefore envision a 2023 where we achieve commercial breakthroughs in our key markets and not only publish the results of already completed validation studies but also initiate new ones, all to continue strengthening our scientific footprint not least in the US. We also expect continued positive sales development. The result of this will result in us positioning the company as an attractive partner for large established players in the market. The opportunities it would open up are very promising for shareholders as well as for patients and healthcare.

**Fredrik Persson, CEO Prostatype Genomics AB**

**Solna, February 16 2023**

## Financial information and comments

### Comparison between October-December 2022 and October-December 2021

#### Net sales

Net sales for the Company amounted to 304 (0) TSEK. The company has not yet begun to sell their product; hence sales are as expected.

#### Operating profit/loss

The operation profit/loss for the Company's 4th quarter 2022 amounted to -8 139 (-5 734) TSEK which is a decrease with approximately 42 % in comparison to prior period. The Company's expenses are mainly in product development, testing and staff.

#### Cash flow from current operations

The cash flow for the 4th quarter amounted to 7 950 (-6 216) TSEK. The cash flow from current operations amounted to -7 850 (-5 381) TSEK. The cash flow for the period is in line with the Company's operating expenses.

#### Cash flow from investment activities

The cash flow from investment activities amounted to 0 (-735) TSEK. From the start of 2022 all product development is carried as expense.

#### Cash flow from financing activities

The cash flow from financing activities amounted -100 (-100) TSEK. Liquid funds as of 31<sup>st</sup> December 2022 amounted to 11 489 (20 329) TSEK.

#### Number of shares

On December 31<sup>st</sup>, 2021, the number of shares was 22 859 497 (15 088 761). Average amount of shares during the 4<sup>th</sup> quarter was 23 019 368.

### Comparison between January 2022 - December 2022 and January 2021 – December 2021

#### Net sales

Net sales for the Company amounted to 683 (10) TSEK. The company is in an initial launch phase in selected markets in EMEA.

#### Operating profit/loss

The operation profit/loss for the period amounted -28 690 (-15 548) TSEK which is a decrease with approximately 85 % in comparison to prior period. The increase is primarily due to the Company's expansion in the USA. Company has continued investing in product development and market.

#### Cash flow from current operations

The cash flow for the period amounted -8 840 (-16 078) TSEK. The cash flow for the period is in line with the Company's operating expenses.

#### Cash flow from investment activities

The cash flow from investment activities amounted to 0 (-2 500) TSEK. From the start of 2022 all product development is carried as expense.

#### Cash flow from financing activities

The cash flow from financing activities amounted 18 853 (23 045) TSEK. Liquid funds as of 31<sup>st</sup> December 2022 amounted to 11 489 (20 329) TSEK. The Company carried out a new share issue in August.

#### Number of shares

On December 31<sup>st</sup>, 2022, the number of shares was 22 859 497 (15 088 761). Average amount of shares for the period was 18 974 129. A list of the major shareholders can be found on the Company's website ([www.prostatypegenomics.com](http://www.prostatypegenomics.com)).

## Prostatype Genomics business and financial ratios

Amounts in SEK	2022-10-01	2021-10-01	2022-01-01	2021-01-01
	2022-12-31	2021-12-31	2022-12-31	2021-12-31
Operating margin	neg	neg	neg	neg
Profit margin	neg	neg	neg	neg
Return on equity	neg	neg	neg	neg
Equity/debt ratio	84%	84%	84%	84%
Equity captial	26 151 033	35 905 840	26 151 033	35 905 840
Cash flow	-7 949 800	-6 216 357	-8 840 443	4 467 388
Number of shares (end of the period)	22 859 497	15 088 761	22 859 497	15 088 761
Number of shares (average for the period)	22 859 497	15 088 761	18 974 129	14 137 816
Number of shares - full dilution (end of the period)	23 019 368	15 248 632	23 019 368	15 248 632
Earnings per share	-0,36	-0,32	-1,27	-1,04
Diluted earnings per share (end of the period)	-0,35	-0,31	-1,26	-1,02
Number of employees (end of the period)	6	6	6	6
Dividend per share	-	-	-	-

### Definition of key ratios

Operating margin	Operating profit/loss after depreciation /net sales
Profit margin	Net profit/loss for the year / net sales
Return on equity	Profit/loss before tax / adjusted equity
Equity/debt ratio	Adjusted equity / total assets
Earnings per share	Net profit/loss for the year / number of shares by period closing
Diluted earnings per share (end of the period)	Net profit/loss for the year / (number of shares + warrants by period closing)

## Financial statement

Amounts in SEK	2022-10-01	2021-10-01	2022-01-01	2021-01-01
	2022-12-31	2021-12-31	2022-12-31	2021-12-31
Net sales	304 313	-	682 798	10 001
Own work capitalized	-	735 019		2 499 641
Other operating income		-		12 186
<b>Total revenue</b>	<b>304 313</b>	<b>735 019</b>	<b>682 798</b>	<b>2 521 828</b>
<b>Operating expenses</b>				
Research and development cost	-728 132	-610 879	-3 507 690	-1 488 110
Other external cost	-4 070 705	-2 840 922	-13 488 884	-8 491 058
Staff cost	-3 167 784	-2 990 616	-10 388 148	-7 980 680
Depreciation, amortization and impairment	-465 506	-22 121	-1 904 302	-88 483
Other operating expenses	-10 967	-4243	-84 067	-21 762
<b>Operating profit/loss</b>	<b>-8 138 781</b>	<b>-5 733 762</b>	<b>-28 690 293</b>	<b>-15 548 265</b>
<b>Income after financial items</b>				
Interest expenses and similiar items				-
Interest expenses and similiar items	-20 261	-19 487	-396 240	-81 493
<b>Profit/loss after financial items</b>	<b>-8 159 042</b>	<b>-5 753 249</b>	<b>-29 086 533</b>	<b>-15 629 758</b>
<b>Profit or loss before tax</b>	<b>-8 159 042</b>	<b>-5 753 249</b>	<b>-29 086 533</b>	<b>-15 629 758</b>
<b>Total profit/loss for the period</b>	<b>-8 159 042</b>	<b>-5 753 249</b>	<b>-29 086 533</b>	<b>-15 629 758</b>

## Balance sheet

(SEK)	2022-12-31	2021-12-31
<b>ASSETS</b>		
<b>Fixed assets</b>		
<i>Intangible assets</i>		
Capitalized development expenditure	16 709 726	18 566 363
Patent		37 175
<b>Total intangible assets</b>	<b>16 709 726</b>	<b>18 603 538</b>
<i>Property, plant and equipment</i>		
Plant and machinery		
Equipment and tools	3 599	14 089
<b>Total property, plant and equipment</b>	<b>3 599</b>	<b>14 089</b>
<i>Financial assets</i>		
Other financial assets	68 136	-
<b>Total financial assets</b>	<b>68 136</b>	<b>-</b>
<b>Total fixed assets</b>	<b>16 781 461</b>	<b>18 617 627</b>
<b>Current assets</b>		
<i>Inventory</i>		
Finished products	43 800	107 520
Advances to suppliers	138 486	74 506
<b>Total current assets</b>	<b>182 286</b>	<b>182 026</b>
<i>Current receivables</i>		
Accounts receivable	502 434	146 573
Other receivables	1 655 830	502 980
Prepaid expenses and accrued income	339 464	424 429
<b>Total current receivables</b>	<b>2 497 728</b>	<b>1 073 982</b>
<i>Short-term investments</i>		
Other short-term investments	6 677 581	10 500 000
<b>Total short-term investments</b>	<b>4 177 581</b>	<b>10 500 000</b>
<i>Cash and bank</i>		
	4 811 151	9 829 175
<b>Total current assets</b>	<b>14 168 746</b>	<b>21 585 183</b>
<b>TOTAL ASSETS</b>	<b>30 950 207</b>	<b>40 202 810</b>

## Balance sheet

(SEK)	2022-12-31	2021-12-31
<b>EQUITY AND LIABILITIES</b>		
<b>Total equity</b>		
<b>Restricted equity</b>		
Share capital	1 371 569	905 326
Development fund	16 709 726	18 566 363
<b>Total restricted equity</b>	<b>18 081 295</b>	<b>19 471 689</b>
<b>Non-restricted equity</b>		
Share premium reserve	149 318 381	130 452 900
Profit/loss brought forward	-112 162 111	-98 388 990
Net profit/loss for the year	-29 086 533	-15 629 758
<b>Total non-restricted equity</b>	<b>8 069 738</b>	<b>16 434 152</b>
<b>Total equity</b>	<b>26 151 033</b>	<b>35 905 840</b>
<b>Long-term liabilities</b>		
Convertible loan	-	
Other debt to credit institutions	466 667	866 667
<b>Total long-term liabilities</b>	<b>466 667</b>	<b>866 667</b>
<b>Current liabilities</b>		
Debt to credit institutions	400 000	400 000
Accounts payable	2 183 975	1 174 708
Tax liabilities	240 286	176 876
Other current liabilities	461 364	212 175
Accrued liabilities and deferred income	1 046 881	1 466 544
<b>Total current assets</b>	<b>4 332 506</b>	<b>3 430 303</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>30 950 207</b>	<b>40 202 810</b>

## Cash flow statement

(SEK)	2022-10-01 2022-12-31	2021-10-01 2021-12-31	2022-01-01 2022-12-31	2021-01-01 2021-12-31
<b>Operating activities</b>				
Profit after financial items	-8 159 042	-5 753 249	-29 086 533	-15 629 758
Adjustments for items not included in cash flow etc	465 506	22 121	1 904 302	88 483
<b>Cash flow from operating activities before changes in working capital</b>	<b>-7 693 536</b>	<b>-5 731 128</b>	<b>-27 182 231</b>	<b>-15 541 275</b>
<b>Cash flow from changes in working capital</b>				
Change in inventory	162 564	91 927	-260	212 921
Change in operating receivables	-120 558	-317 422	-1 423 746	125 480
Change in operating liabilities	-198 271	575 286	912 855	-875 336
<b>Cash flow from current operations</b>	<b>-7 849 800</b>	<b>-5 381 338</b>	<b>-27 693 382</b>	<b>-16 078 210</b>
<b>Investment activities</b>				
Acquisition of intangibles		-735 019		-2 499 641
Acquisition of fixed assets		-		-
<b>Cash flow from investment activities</b>		<b>-735 019</b>		<b>-2 499 641</b>
<b>Financing activities</b>				
Paid-in option premium		-		-
Net issue liquidity incl. bridge loan		-	19 252 938	23 245 239
Received convertible loans		-		-
Amortization	-100 000	-100 000	-400 000	-200 000
<b>Cash flow from financing activities</b>	<b>-100 000</b>	<b>-100 000</b>	<b>18 852 939</b>	<b>23 045 239</b>
<b>Cash flow for the period</b>	<b>-7 949 800</b>	<b>-6 216 357</b>	<b>-8 840 443</b>	<b>4 467 388</b>
<b>Opening liquid funds</b>	<b>19 438 532</b>	<b>26 545 531</b>	<b>20 329 175</b>	<b>15 861 788</b>
<b>Closing liquid funds</b>	<b>11 488 732</b>	<b>20 329 175</b>	<b>11 488 732</b>	<b>20 329 175</b>

## Changes in equity

### 1 January 2022 – 31 December 2022

SEK	Share capital	Development fund	Share premium reserve	Accumulated profit/loss
Opening balance	905 325	18 566 363	130 452 900	-114 018 748
Transfer to development fund		-1 856 636		1 856 636
New share issue	466 244		22 104 639	
Expenses of the issue			-3 239 158	
Result for the period				-29 086 533
<b>Closing balance</b>	<b>1 371 569</b>	<b>16 709 727</b>	<b>149 318 381</b>	<b>-141 248 645</b>

### 1 January 2021 – 31 December 2021 (rev.)

SEK	Share capital	New share issues in progress	Development fund	Share premium reserve	Accumulated profit/loss
Opening balance	791 212		16 066 722	107 321 774	-95 889 349
New share issue	114 113			24 610 470	
Expenses of the issue				-1 479 344	
Option premium					
Transfer to development fund			2 499 641		-2 499 641
Result for the period					-15 629 758
<b>Closing balance</b>	<b>905 325</b>	<b>0</b>	<b>18 566 363</b>	<b>130 452 900</b>	<b>-114 018 748</b>



## General information

### Company information

Prostatype Genomics AB with organization number 556726-0285 is a limited company registered in Sweden, domiciled in Stockholm. The address is Gustaf III:s Boulevard 34, 169 73 Solna. The company is engaged in the research and developments of medical devices. The Company is listed on NASDAQ First North with the ticker PROGEN.ST.

In this report, Prostatype Genomics AB is called either by its full name or as “the Company”, alternatively as Prostatype. All figures in the report are in thousands of Swedish kronor (TSEK) if not otherwise specified.

The Company is the result of more than ten years of research into the genomics of prostate cancer. The Company was founded in 2007 as a spin off from Cancer Center Karolinska (Karolinska Institutet, Stockholm). The result was the development of the today CE-marked and market ready product Prostatype® Test System. Prostatype® is a test for diagnosis and prognosis that has been developed to provide the complementary information that is often needed for the selection of the optimal treatment strategy for each patient. The test analyzes the gene expression in cancer cells from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed. Aided by AI (Artificial Intelligence) technology, the gene test of Prostatype Genomics makes it possible to make a better prognosis and to classify the patient’s illness into different risk types. In that way the Company can reduce the risk of over- or under treatment, which in many cases lead to great discomfort for the patient. Prostatype® is today the only gene test for prostate cancer that is available in kit format. The product is also very scalable in terms of volume due to the algorithm that forms the basis of the test.

### Accounting principles

The year-end report has been prepared in accordance with BFNAR 2012:1 Årsredovisning och koncernredovisning (K3) issued by the Swedish Accounting Standards Boards (BFN). The accounting policy for the Company complies with applied accounting principles for the most recent published annual report.

### Related party transactions

During the period from January 1 2022 to December 31 2022, except for what is detailed below, no related party transactions have taken place.

The Company has during the period procured services for in total 399 086 (1 008 002) SEK from the company SecureAppbox AB, which is a supplier of web-based solutions for P-score. Håkan Englund, Member of the Board of Prostatype Genomics AB, is the Chairman of the Board of SecureAppbox. Håkan Englund has not taken part in the procurement process for these services.

Transactions with related parties have been performed on market terms.

### Profit disposition

The Board is not intending to propose any dividend at the coming General Meeting.

### Risk factors

For a description of the most significant market- and operational risk, please see the recent prospectus that is published on the Company’s web page [www.prostatypegenomics.com](http://www.prostatypegenomics.com) under the heading Investor Relations.

## Other information

### Dates for publication of financial information

Annual Report 2022	2023-05-04
Annual General Meeting	2023-06-01
Quarter 1	2023-05-11
Quarter 2	2023-08-17
Quarter 3	2023-11-10
Quarter 4 & Year End Report 2023	2024-02-15

This interim report, as well as further information, is available at Prostatype Genomics' web page, [www.prostatypegenomics.com](http://www.prostatypegenomics.com)

### Certified Advisor

Svensk Kapitalmarknadsgranskning AB, 011-32 30 732, [ca@skmg.se](mailto:ca@skmg.se).

### Review of interim report

This interim report has not been subject to review by the Company's auditors

### Publication

*This information is such information that Prostatype Genomics AB, is obliged to publish in accordance with the EU market abuse regulation. The information is published by the below contact person, for publication on 16 February 8.00 AM. All information is given also in a Swedish version, and in case of any discrepancies, the Swedish version prevails. Fredrik Persson, VD, 073-049 77 01, [fredrik.persson@prostatypegenomics.com](mailto:fredrik.persson@prostatypegenomics.com) This interim report gives an accurate overview of the Company's operations, financial status and results.*

Fredrik Persson, VD, 073-049 77 01, [fredrik.persson@prostatypegenomics.com](mailto:fredrik.persson@prostatypegenomics.com)

### Solna 16 February 2023

---

Anders Lundberg  
Chairman of the Board

---

Håkan Englund  
Director

---

Michael Häggman  
Director

---

Karlheinz Schmelig  
Director

---

Mattias Prage  
Director

---

Fredrik Persson  
CEO



**Prostatype Genomics AB**

Industrivägen 19, SE-171 48 Solna

Telefon:

+46 (0)8-20 87 00

Hemsida:

[www.prostatypegenomics.com](http://www.prostatypegenomics.com)